Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s

Chirality

Volumn 15, Issue 4, 2003, Pages 333-339

  Narimatsu, Shizuo ^a   Takemi, Chie ^a   Kuramoto, Shino ^a   Tsuzuki, Daisuke ^a   Hichiya, Hiroyuki ^a   Tamagake, Keietsu ^a   Yamamoto, Shigeo ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

1 hydroxylation; Active metabolite; Bufuralol; CYP2C19; CYP2D6; HPLC; Pharmacological activity; Product stereoselectivity

Indexed keywords

1'' HYDROXYBUFURALOL; 1'' OXOBUFURALOL; 3 HYDROXYLASE; 4 HYDROXYLASE; 6 HYDROXYLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; BUNITROLOL; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DIAZEPAM; ETHOXYRESORUFIN DEETHYLASE; HYDROXYBUFURALOL; MEPHENYTOIN; OXYGENASE; PROCAINAMIDE; RECOMBINANT ENZYME; TOLBUTAMIDE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER; LIVER MICROSOME; METABOLITE; NONHUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; STEREOCHEMISTRY;

ADRENERGIC BETA-ANTAGONISTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ETHANOLAMINES; HUMANS; HYDROXYLATION; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; RECOMBINANT PROTEINS; STEREOISOMERISM; SUBSTRATE SPECIFICITY;

EID: 0037267421     PISSN: 08990042     EISSN: None     Source Type: Journal    
DOI: 10.1002/chir.10212     Document Type: Conference Paper

References (17)

1. Fothergill GA, Osbond JM, Wicknens JC. Bufuralol, a new betaadrenoceptor blocking agent. 1. Synthesis and structure-activity studies in a series of benzofuran-2-ethanolamines. Arzneim Forsch Drug Res 1977;27:978-981.
2. Hamilton TC, Parkes MW. Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamine. Arzneim Forsch Drug Res 1977;27:1410-1417.
3. Francis RJ, East PB, Larman J. Kinetics and metabolism of (+)-, (-)- and (±)-bufuralol. Eur J Clin Pharmacol 1982;23:529-533.
4. Hamilton TC, Chapman V. Intrinsic sympathomimetic activity of βadrenoceptor blocking agent at cardiac and vascular β-adrenoceptors. Life Sci 1978;23:813-820.
5. Machin PJ, Hurst ND, Osbond JM. β-Adrenoceptor activity of the stereoisomers of the bufufralol alcohol and ketone metabolites. J Med Chem 1985;28:1648-1651.
6. Dayer P, Balant L, Courvoisier F, Kupfer A, Kubli A, Gorgia A, Fabre J. The genetic control of bufuralol metabolism in man. Eur Drug Metab Pharmacokinet 1982;7:73-77.
7. Minder EI, Meier PJ, Muller HK, Minder C, Meyer UA. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation. Eur J Clin Invest 1984;14:184-189.
8. Dayer P, Gasser R, Gut J, Kronbach T, Robertz GM, Eichelbaum M, Meyer UA. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) increased Michaelis is constant (Km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizers. Biochem Biophys Res Commun 1984;125:374-380.
9. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, Guengerich FP. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1985;260:9057-1967.
10. Gut J, Catin T, Dayer P, Kronbach T, Zanger U, Meyer UA. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol. J Biol Chem 1986;261:11734-11743.
11. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269.
12. Yamazaki H, Guo Z, Persmark M, Mimura M, Inoue K, Guengerich FP, Shimada T. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 1994;46:568-577.
13. Mankowski DC. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6. Drug Metab Dispos 1999; 27:1024-1028.
14. Weerawarna SA, Geisshusler SM, Murthy SS, Nelson WL. Enantioselective and diastereoselective hydroxylation of bufuralol. Absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2-(tert-butylamino)ethyl]benzofurans, the benzylic hydroxylation metabolites. J Med Chem 1991;34:3091-3097.
15. Mautz DS, Nelson WL, Shen DD. Regioselective and stereoselective oxidation of metoprolol and bufuralol catalyzed by microsomes containing cDNA-expressed human P4502D6. Drug Metab Dispos 1995; 23:513-517.
16. Narimatsu S, Takemi C, Tsuzuki D, Kataoka H, Yamamoto S, Shimada N, Satoh T, Meyer UA, Gonzale FJ. Stereoselective metabolism of bufuralol racemate and enantiomers in human liver microsomes. J Pharmacol Exp Ther 2002;303:172-178.
17. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.